scopolamine butylbromide

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Dose	Unit	Route
60	mg	O
60	mg	P
60	mg	R

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.69 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Property	Description	Value
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,NTRK2,PDK1,PDK4,PRKDC,TEK,TGFBR1	18
kinase-selectivity-class	EIF2AK3,GRK2,MAP2K6	3
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abdominal pain	154.01	16.85	228	12254	395493	90220472
Swelling face	104.81	16.85	88	12394	81264	90534701
Swollen tongue	102.32	16.85	69	12413	45887	90570078
Angioedema	91.55	16.85	74	12408	64802	90551163
Nail bed inflammation	90.60	16.85	25	12457	1776	90614189
Streptococcal sepsis	89.65	16.85	29	12453	3555	90612410
Constipation	87.25	16.85	146	12336	280249	90335716
Nasal mucosal disorder	85.28	16.85	24	12458	1833	90614132
Dysphonia	84.90	16.85	70	12412	63014	90552951
Pseudomonal sepsis	76.74	16.85	27	12455	4275	90611690
Vascular device infection	73.68	16.85	35	12447	11917	90604048
Metastases to central nervous system	71.95	16.85	39	12443	17503	90598462
Candida infection	68.40	16.85	48	12434	34009	90581956
Drug ineffective for unapproved indication	67.65	16.85	63	12419	66581	90549384
Paronychia	66.95	16.85	29	12453	7977	90607988
Varicose vein	56.28	16.85	25	12457	7302	90608663
Colitis	55.85	16.85	58	12424	69884	90546081
Metastases to lymph nodes	53.61	16.85	28	12454	11661	90604304
Sepsis	52.37	16.85	91	12391	179723	90436242
Hydronephrosis	52.05	16.85	28	12454	12374	90603591
Brain oedema	48.27	16.85	30	12452	17355	90598610
Vomiting	45.16	16.85	221	12261	788072	89827893
Lymphoedema	44.02	16.85	26	12456	13727	90602238
Nausea	42.94	16.85	280	12202	1110036	89505929
Restlessness	42.62	16.85	37	12445	35683	90580282
Diarrhoea	38.82	16.85	241	12241	938949	89677016
Starvation ketoacidosis	36.46	16.85	8	12474	217	90615748
Arthropathy	36.39	16.85	4	12478	366238	90249727
Systemic lupus erythematosus	35.84	16.85	4	12478	361892	90254073
Lip swelling	34.43	16.85	34	12448	38576	90577389
Off label use	34.40	16.85	264	12218	1101988	89513977
Skin fissures	34.22	16.85	26	12456	20783	90595182
Glossodynia	33.31	16.85	3	12479	321776	90294189
Infective exacerbation of chronic obstructive airways disease	33.04	16.85	11	12471	1475	90614490
Synovitis	31.77	16.85	4	12478	329748	90286217
Morbid thoughts	31.27	16.85	9	12473	745	90615220
Naevus haemorrhage	29.14	16.85	6	12476	119	90615846
Aphonia	28.61	16.85	19	12463	12300	90603665
Intestinal obstruction	26.46	16.85	29	12453	37102	90578863
Pulmonary artery stenosis congenital	25.93	16.85	7	12475	458	90615507
Chemical burns of eye	25.24	16.85	5	12477	81	90615884
Purulent discharge	24.93	16.85	13	12469	5392	90610573
Drug diversion	24.28	16.85	8	12474	1039	90614926
Arthropod bite	24.01	16.85	15	12467	8752	90607213
Enterocolitis	23.93	16.85	16	12466	10474	90605491
Urinary tract infection	23.72	16.85	94	12388	305538	90310427
Colitis ulcerative	23.70	16.85	35	12447	60231	90555734
Obstructive pancreatitis	23.28	16.85	7	12475	674	90615291
Eczema	22.68	16.85	32	12450	52838	90563127
Contraindicated product administered	22.49	16.85	8	12474	320131	90295834
Treatment failure	22.39	16.85	7	12475	303921	90312044
Impaired healing	22.17	16.85	3	12479	234196	90381769
Essential tremor	21.93	16.85	8	12474	1404	90614561
Blood creatinine increased	21.66	16.85	45	12437	101341	90514624
Helicobacter infection	21.25	16.85	3	12479	226847	90389118
Metastatic gastric cancer	21.16	16.85	5	12477	190	90615775
Jaundice	20.78	16.85	24	12458	32493	90583472
Adrenocortical insufficiency acute	20.38	16.85	9	12473	2592	90613373
Malaise	20.24	16.85	144	12338	585842	90030123
Bowel movement irregularity	20.02	16.85	12	12470	6502	90609463
Nephrolithiasis	20.01	16.85	29	12453	49056	90566909
Pharyngeal swelling	19.92	16.85	14	12468	9930	90606035
Intestinal perforation	19.91	16.85	16	12466	13865	90602100
Anorectal malformation	19.91	16.85	5	12477	246	90615719
Atrial septal defect	19.85	16.85	13	12469	8221	90607744
Allergic cough	19.81	16.85	7	12475	1121	90614844
Infusion related reaction	19.78	16.85	17	12465	416763	90199202
Subcutaneous abscess	19.77	16.85	12	12470	6654	90609311
Abdominal discomfort	19.74	16.85	22	12460	477306	90138659
Hepatitis E	19.63	16.85	8	12474	1891	90614074
Therapeutic product effect decreased	19.38	16.85	7	12475	277564	90338401
Alopecia	19.20	16.85	24	12458	495047	90120918
Oligohydramnios	18.92	16.85	12	12470	7189	90608776
Faeces hard	18.48	16.85	9	12473	3233	90612732
Skin warm	18.20	16.85	12	12470	7675	90608290
Drug abuse	18.12	16.85	37	12445	82310	90533655
Encephalopathy neonatal	17.70	16.85	3	12479	19	90615946
Stomatitis	17.44	16.85	8	12474	274690	90341275
Pericarditis	16.95	16.85	8	12474	270143	90345822

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abdominal pain	49.50	18.60	83	4847	190388	42426017
Pancreatic neoplasm	39.52	18.60	11	4919	963	42615442
Genitalia external ambiguous	37.34	18.60	8	4922	232	42616173
Congenital bladder anomaly	36.06	18.60	8	4922	274	42616131
Foetal hypokinesia	33.48	18.60	8	4922	382	42616023
Neonatal respiratory depression	32.06	18.60	8	4922	458	42615947
Foetal exposure during pregnancy	31.84	18.60	33	4897	47278	42569127
Anomaly of external ear congenital	30.38	18.60	6	4924	115	42616290
Anal stenosis	29.22	18.60	7	4923	338	42616067
Diarrhoea	28.70	18.60	117	4813	460732	42155673
External auditory canal atresia	27.65	18.60	6	4924	185	42616220
Hyperaesthesia	25.90	18.60	13	4917	5939	42610466
Vomiting	25.13	18.60	82	4848	289641	42326764
Tumour invasion	23.58	18.60	6	4924	372	42616033
Interleukin level increased	22.49	18.60	7	4923	903	42615502
Oral mucosal blistering	22.24	18.60	9	4921	2492	42613913
Faeces hard	21.83	18.60	8	4922	1696	42614709
Respiratory disorder neonatal	20.70	18.60	8	4922	1962	42614443
Neuroleptic malignant syndrome	20.16	18.60	18	4912	21454	42594951
Abdominal pain upper	20.06	18.60	35	4895	82574	42533831
Atrial septal defect	19.80	18.60	12	4918	7907	42608498
Gastritis erosive	19.27	18.60	11	4919	6492	42609913
Decubitus ulcer	19.07	18.60	13	4917	10464	42605941
Lactose intolerance	19.03	18.60	7	4923	1499	42614906
Intercepted product storage error	18.74	18.60	5	4925	373	42616032
Hepatitis alcoholic	18.73	18.60	5	4925	374	42616031

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

scopolamine butylbromide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abdominal pain	171.12	14.95	286	16041	512703	110060269
Swollen tongue	106.85	14.95	81	16246	60281	110512691
Swelling face	97.49	14.95	92	16235	92229	110480743
Nail bed inflammation	90.36	14.95	26	16301	2004	110570968
Nasal mucosal disorder	87.77	14.95	25	16302	1858	110571114
Constipation	81.95	14.95	170	16157	357616	110215356
Streptococcal sepsis	81.49	14.95	30	16297	5042	110567930
Dysphonia	76.99	14.95	74	16253	75855	110497117
Pseudomonal sepsis	64.72	14.95	30	16297	9016	110563956
Vascular device infection	63.40	14.95	36	16291	16476	110556496
Angioedema	62.69	14.95	75	16252	98425	110474547
Metastases to central nervous system	62.39	14.95	40	16287	22777	110550195
Diarrhoea	61.38	14.95	330	15997	1139175	109433797
Vomiting	59.77	14.95	279	16048	910396	109662576
Varicose vein	59.12	14.95	26	16301	6914	110566058
Paronychia	58.93	14.95	30	16297	11051	110561921
Candida infection	54.83	14.95	50	16277	47959	110525013
Metastases to lymph nodes	47.78	14.95	29	16298	15003	110557969
Nausea	47.51	14.95	328	15999	1235362	109337610
Drug ineffective for unapproved indication	46.25	14.95	66	16261	102772	110470200
Colitis	45.04	14.95	65	16262	102258	110470714
Restlessness	39.38	14.95	45	16282	56214	110516758
Hydronephrosis	37.14	14.95	28	16299	20637	110552335
Sepsis	34.04	14.95	116	16211	327230	110245742
Lymphoedema	33.16	14.95	23	16304	14906	110558066
Neutropenic sepsis	33.12	14.95	31	16296	30715	110542257
Intestinal obstruction	32.98	14.95	40	16287	53187	110519785
Enterocolitis	32.57	14.95	25	16302	18924	110554048
Malaise	32.29	14.95	189	16138	671630	109901342
Arthropathy	31.55	14.95	3	16324	287519	110285453
Lip swelling	31.27	14.95	38	16289	50629	110522343
Brain oedema	30.92	14.95	30	16297	31068	110541904
Pancreatic neoplasm	30.05	14.95	11	16316	1818	110571154
Skin fissures	28.95	14.95	26	16301	24432	110548540
Morbid thoughts	28.89	14.95	9	16318	910	110572062
Naevus haemorrhage	28.73	14.95	6	16321	119	110572853
Faeces hard	27.05	14.95	13	16314	4233	110568739
Aphonia	26.67	14.95	19	16308	12841	110560131
Urinary tract infection	26.67	14.95	107	16220	326175	110246797
Anorectal malformation	26.45	14.95	5	16322	58	110572914
Pharyngeal swelling	25.47	14.95	18	16309	12014	110560958
Neuroleptic malignant syndrome	25.12	14.95	28	16299	34031	110538941
Synovitis	25.05	14.95	5	16322	274087	110298885
Off label use	24.25	14.95	332	15995	1499853	109073119
Infective exacerbation of chronic obstructive airways disease	24.13	14.95	11	16316	3179	110569793
Eczema	23.55	14.95	40	16287	72253	110500719
Chemical burns of eye	23.23	14.95	5	16322	115	110572857
Glossodynia	22.63	14.95	3	16324	222001	110350971
Systemic lupus erythematosus	22.50	14.95	5	16322	254333	110318639
Jaundice	22.31	14.95	35	16292	59201	110513771
Levator syndrome	21.98	14.95	4	16323	37	110572935
Metastatic gastric cancer	21.85	14.95	6	16321	390	110572582
Arthropod bite	21.71	14.95	15	16312	9656	110563316
Purulent discharge	20.81	14.95	13	16314	7070	110565902
Nephrolithiasis	20.73	14.95	36	16291	66176	110506796
Allergic cough	19.93	14.95	7	16320	1028	110571944
Tumour invasion	19.57	14.95	6	16321	575	110572397
Discomfort	19.44	14.95	4	16323	214703	110358269
Borderline personality disorder	19.44	14.95	7	16320	1105	110571867
Essential tremor	19.26	14.95	8	16319	1850	110571122
Impaired healing	19.25	14.95	3	16324	196714	110376258
Treatment failure	18.33	14.95	9	16318	277225	110295747
Pericarditis	18.04	14.95	5	16322	219109	110353863
Therapeutic product effect decreased	17.62	14.95	7	16320	244309	110328663
Intestinal perforation	16.81	14.95	18	16309	20926	110552046
Haematochezia	16.72	14.95	46	16281	115478	110457494
Enteritis	16.33	14.95	17	16310	19139	110553833
Perforation	16.13	14.95	7	16320	1803	110571169
Cholangitis acute	15.76	14.95	7	16320	1906	110571066
Back pain	15.64	14.95	101	16226	370895	110202077
Colitis ulcerative	15.63	14.95	35	16292	77328	110495644
Skin warm	15.54	14.95	12	16315	9158	110563814
Subcutaneous abscess	15.37	14.95	12	16315	9305	110563667
Helicobacter infection	15.25	14.95	4	16323	181873	110391099
Vulvovaginal swelling	15.15	14.95	5	16322	608	110572364
Administration site swelling	15.01	14.95	5	16322	626	110572346

Source	Code	Description
ATC	A03BB01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS BELLADONNA AND DERIVATIVES, PLAIN Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
ATC	A03DB04	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH ANALGESICS Belladonna and derivatives in combination with analgesics
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
CHEBI has role	CHEBI:48876	muscarinic antagonist
CHEBI has role	CHEBI:53784	antispasmodic drug
CHEBI has role	CHEBI:35480	analgesic

Species	Use	Relation
Horses	Abdominal pain (colic) associated with spasmodic colic	Indication
Horses	Flatulent colic	Indication
Horses	Simple impactions	Indication

Target	Class	Pharos	UniProt	Bioact source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	WOMBAT-PK

ID	Source
1085787	RXNORM
C0006519	UMLSCUI
CHEBI:32123	CHEBI
CHEMBL1256901	ChEMBL_ID
6852391	PUBCHEM_CID
CHEMBL1618102	ChEMBL_ID
149-64-4	SECONDARY_CAS_RN
DB09300	DRUGBANK_ID
1156229000	SNOMEDCT_US
395739004	SNOMEDCT_US
D002086	MESH_DESCRIPTOR_UI
2Z3E1OF81V	UNII
003459	NDDF